IN2012DN03379A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03379A
IN2012DN03379A IN3379DEN2012A IN2012DN03379A IN 2012DN03379 A IN2012DN03379 A IN 2012DN03379A IN 3379DEN2012 A IN3379DEN2012 A IN 3379DEN2012A IN 2012DN03379 A IN2012DN03379 A IN 2012DN03379A
Authority
IN
India
Prior art keywords
present
spore
relates
coated
vaccine
Prior art date
Application number
Inventor
Simon Michael Cutting
Hong Anh Huynh
Original Assignee
New Royal Holloway & Bedford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Royal Holloway & Bedford filed Critical New Royal Holloway & Bedford
Publication of IN2012DN03379A publication Critical patent/IN2012DN03379A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
IN3379DEN2012 2009-09-21 2010-09-21 IN2012DN03379A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916570.5A GB0916570D0 (en) 2009-09-21 2009-09-21 Method
PCT/GB2010/001771 WO2011033275A1 (en) 2009-09-21 2010-09-21 Bacterial spore having therapeutic agent adsorbed on its surface

Publications (1)

Publication Number Publication Date
IN2012DN03379A true IN2012DN03379A (en) 2015-10-23

Family

ID=41278080

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3379DEN2012 IN2012DN03379A (en) 2009-09-21 2010-09-21

Country Status (6)

Country Link
US (1) US8673311B2 (en)
EP (1) EP2480241A1 (en)
CN (1) CN102630163A (en)
GB (1) GB0916570D0 (en)
IN (1) IN2012DN03379A (en)
WO (1) WO2011033275A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
BR122023020925A2 (en) 2014-09-17 2024-01-30 Spogen Biotech Inc VACCINE TO PRODUCE AN IMMUNOGENIC RESPONSE IN AN INDIVIDUAL
WO2021055474A1 (en) * 2019-09-16 2021-03-25 Microbiome Labs, Llc Spore-based probiotic supplementation in chickens and effect on salmonella loads
CN110904002B (en) * 2019-11-25 2022-04-29 天津大学 Method for biologically removing tetracycline antibiotics
EP3842052A1 (en) 2019-12-23 2021-06-30 Senzyme GmbH Composition and methods for stabilising intestinal flora and improving hygiene
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
FR2798291B1 (en) * 1999-09-10 2005-01-14 Pasteur Institut IMMUNOGENIC ACELLULAR COMPOSITIONS AND VACCINE ACELLULAR COMPOSITIONS AGAINST BACILLUS ANTHRACIS
WO2002000232A2 (en) 2000-06-26 2002-01-03 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
WO2010006326A2 (en) 2008-07-11 2010-01-14 Tufts University Methods and compositions for spore-based vaccines

Also Published As

Publication number Publication date
GB0916570D0 (en) 2009-10-28
US8673311B2 (en) 2014-03-18
US20120237544A1 (en) 2012-09-20
EP2480241A1 (en) 2012-08-01
WO2011033275A1 (en) 2011-03-24
CN102630163A (en) 2012-08-08

Similar Documents

Publication Publication Date Title
CY1123958T1 (en) METHOD OF PREPARATION OF CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES
MX351464B (en) Methods for the treatment of allergic diseases.
TN2011000673A1 (en) Bace inhibitors
IN2012DN03883A (en)
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX340555B (en) Antibodies against il-18r1 and uses thereof.
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
IN2012DN03379A (en)
MX2014009750A (en) Antifungal compositions for the treatment of skin and nails.
MX2013007312A (en) Flame treatment of a substrate.
UA112760C2 (en) THEOBROMIN IN COMBINATION WITH GUYPHENESINE FOR THE TREATMENT OF Cough
MX2012010127A (en) Derivatives of aminoindanes, their preparation and their application in therapeutics.
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
MX2011011059A (en) Use of propineb as bird repellent.
MX2011006721A (en) Pharmaceutical formulation of nanonised fenofibrate.
UA110626C2 (en) Process for preparing pan-cdk inhibitors of the formula (i), and also to intermediates in the preparation
WO2012065028A3 (en) Substituted tetracyclines
MX2013005825A (en) Benzoxazepines as inhibitors of mtor and methods of their use and manufacture.
GR20120100608A (en) Pre-assembled exhibition construction
MX2013006526A (en) Dosages of arylsulfonamide derivatives.
UA41922U (en) Use of altan as radioprotector
UA94339C2 (en) use of Corvitine as frigoprotective agent